Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of midostaurin with chemotherapy and as post-consolidation monotherapy in pediatric untreated FLT3-mutated AML
KCT0004051Phase 2Recruiting
- Sponsor
- Novartis
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midostaurin in acute myeloid leukemia (AML), sponsored by Novartis. Primary endpoints: Safety of midostaurin combined with chemotherapy and as post-consolidation monotherapy, Efficacy of midostaurin in combination and as maintenance and 1 more. Started May 2019; status: recruiting.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on KCT0004051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004051.